A leading light in clinical discovery
A leading light in clinical discovery

Leading clinical discovery is about improving care for as many patients as possible, which is exactly what NM/CT 870 DR was designed to do. It’s a premium SPECT/CT system with the added flexibility of a standalone CT that includes the latest advancements in dose and metal artifact reduction technology. It delivers the accurate, reproducible results referring physicians require in a comfortable and streamlined exam experience, so you can lead clinical discovery with hybrid imaging.
TECHNOLOGY

Full spectrum of SPECT/CT capability

A fully digital vision for nuclear medicine

PRODUCTIVITY

Switch to an all-digital workflow with SmartConsole

One home for all of your molecular images

FUTURE-READY

A system that’s ready for the future when you are

PATIENT EXPERIENCE

Make the most of their time

An evolution in SPECT dose management

Innovative CT dose reduction technology

QUANTITATION

Quantitative SPECT/CT for every patient, every day

Built for quantitation

QUANTITATIVE APPLICATIONS

Inform your decisions with measurable results

SUMMARY

A SPECT/CT system for true discovery

Related Products

  • 1 Compared to LEHR collimator, with Step & Shoot scan mode (for SPECT) / without Clarity 2D (for Planar). As demonstrated in phantom testing using a bone scan protocol, Evolution processing (for SPECT), and a model observer. Because model observer results may not always match those from a human reader, the actual time/dose reduction depends on the clinical task, patient size, anatomical location and clinical practice. A radiologist should determine the appropriate scan time/ dose for the particular clinical task.
  • 2 Image quality as defined by an Artifact Index in Phantom testing. Data on file.
  • 3 As demonstrated in phantom testing using a model observer. For SPECT, compared to using the LEHR Collimator and a SPECT Step & Shoot acquisition. For Planar, compared to using LEHR without Clarity 2D.
  • 4 In clinical practice, Evolution options4a (Evolution for Bone, Evolution for Cardiac, Evolution for Bone Planar) and Evolution Toolkit4b are recommended for use following consultation of a Nuclear Medicine physician, physicist and/or application specialist to determine the appropriate dose or scan time reduction to obtain diagnostic image quality for a particular clinical task, depending on the protocol adopted by the clinical site.
  • 4a Evolution Options - Evolution claims are supported by simulation of count statistics using default factory protocols and imaging of 99mTc based radiotracers with LEHR collimator on anthropomorphic phantom or realistic NCAT – SIMSET phantom followed by quantitative and qualitative images comparison.
  • 4b Evolution Toolkit - Evolution Toolkit claims are supported by simulation of full count statistics using lesion simulation phantom images based on various radiotracers and collimators and by showing that SPECT image quality reconstructed with Evolution Toolkit provide equivalent clinical information but have better signal-to-noise, contrast, and lesion resolution compared to the images reconstructed with FBP / OSEM.
  • 5 In clinical practice, the use of ASiR or VISR may reduce CT patient dose depending on the clinical task, patient size, anatomical location and clinical practice. A consultation with a radiologist and a physicist should be made to determine the appropriate dose to obtain diagnostic image quality for the particular clinical task.
  • 6 Quantitative accuracy defined as equivalence to well counter-measured injected activity in a test phantom. Equivalence means <11% difference when comparing measured counts in SPECT studies corrected by Q.AC-reconstructed CTAC to measured counts in studies corrected by benchmark reconstructed CTAC. Measured counts are defined as average within identical ROIs positioned on SPECT reconstructed slices of homogenous 99mTc solution phantom study.